← Back to Search

Transcranial Magnetic Stimulation

TMS for Depression

N/A

Waitlist Available

Research Sponsored by University of California, Los Angeles

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 weeks (baseline and final visit)

Awards & highlights

Study Summary

This trial will determine if a-rTMS at different frequencies can safely & tolerably treat Major Depressive Disorder. 30 participants will be tested over 2 weeks.

Who is the study for?

This trial is for adults aged 18-65 with moderate to severe Major Depressive Disorder, who haven't improved after trying at least two different types of antidepressants and psychotherapy. Participants must be able to commit to an accelerated treatment schedule but can't join if they have certain neurological conditions, risk of seizures, psychotic disorders, or magnetic-sensitive implants in their body.Check my eligibility

What is being tested?

The study tests the safety and effectiveness of a non-standard frequency accelerated repetitive Transcranial Magnetic Stimulation (a-rTMS) on patients hospitalized with depression. It involves brain activity recordings, one MRI scan, determining individual TMS settings, daily symptom checks, and receiving 25 TMS treatments over up to two weeks.See study design

What are the potential side effects?

Potential side effects may include discomfort at the stimulation site on the scalp, headache following treatment sessions or rarely seizures. Other less common side effects might involve lightheadedness or temporary hearing changes due to the noise during treatment.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 weeks (baseline and final visit)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 weeks (baseline and final visit)

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks (baseline and final visit) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Treatment Efficacy as Measured by Change in Inventory of Depressive Symptoms (Self-Report) at Baseline and Final Visit

Secondary outcome measures

Treatment Efficacy as Measured by Change in Patient Health Questionnaire-9 (PHQ-9) at Baseline and Final Visit.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Open-label TMSExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor

1,534 Previous Clinical Trials

10,267,366 Total Patients Enrolled

101 Trials studying Depression

48,413 Patients Enrolled for Depression

Media Library

Open-label TMS (Transcranial Magnetic Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05645575 — N/A

Depression Research Study Groups: Open-label TMS

Depression Clinical Trial 2023: Open-label TMS Highlights & Side Effects. Trial Name: NCT05645575 — N/A

Open-label TMS (Transcranial Magnetic Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05645575 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research include elderly participants?

"The parameters for enrollment in this study stipulate that patients must be aged 18 to 65. Separately, there are 215 trials dedicated to minors and 1019 studies targeting geriatric individuals."

Answered by AI

Are there opportunities for patients to partake in this experiment?

"The trial, which was posted on 22nd of January 2023 and last updated 8th May 2023 is not currently actively recruiting candidates. However, there are plenty other studies requiring participants at this time with 1,379 trials listed online."

Answered by AI

How might I be able to become involved in this clinical research?

"The research team is searching for 30 adults, aged 18-65 who suffer from depression. Additionally, the potential candidates must have a HAM-D score of 17 or higher; two failed trials with different antidepressant medications; exposure to at least two evidence-based augmentation therapies (benzodiazepines excluded); and completed psychotherapy known to be effective in treating MDD frequently and sufficiently. Lastly, participants need to agree that they are able and willing to stick with an accelerated treatment protocol."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

In-patient SCC TMS

Andrew F. Leuchter 2023. "In-patient SCC TMS". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05645575.